LeMaitre Vascular, Inc. (NASDAQ:LMAT) Given Consensus Rating of "Hold" by Analysts

Key Points

• LeMaitre Vascular, Inc. (NASDAQ:LMAT) has received an average analyst rating of "Hold", with three hold ratings and two buy ratings from brokerages.
• The company's shares opened at $95.62, experiencing a 1.5% decrease in trading, while its market capitalization stands at $2.16 billion.
• LeMaitre Vascular reported $0.60 earnings per share for the last quarter, slightly exceeding analysts' expectations, and has set a guidance for FY 2025 of 2.230-2.370 EPS.

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Get Free Report) have been assigned an average rating of "Hold" from the five brokerages that are currently covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $97.60.

LMAT has been the subject of several research reports. Cantor Fitzgerald lifted their price target on LeMaitre Vascular from $92.00 to $95.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Barrington Research raised LeMaitre Vascular from a "market perform" rating to an "outperform" rating and set a $95.00 price target for the company in a report on Wednesday, August 6th.

LeMaitre Vascular Stock Down 2.1%

NASDAQ LMAT traded down $1.94 during trading hours on Wednesday, hitting $92.29. 77,956 shares of the company traded hands, compared to its average volume of 170,861. The business's 50-day moving average is $89.69 and its 200-day moving average is $86.06. LeMaitre Vascular has a twelve month low of $71.42 and a twelve month high of $109.58. The company has a debt-to-equity ratio of 0.46, a quick ratio of 11.74 and a current ratio of 13.96. The stock has a market capitalization of $2.09 billion, a price-to-earnings ratio of 44.80, a P/E/G ratio of 2.42 and a beta of 0.79.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 EPS for the quarter, beating the consensus estimate of $0.57 by $0.03. The firm had revenue of $63.15 million during the quarter, compared to analysts' expectations of $62.48 million. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%.The business's quarterly revenue was up 15.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.52 earnings per share. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. Sell-side analysts anticipate that LeMaitre Vascular will post 1.94 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, September 4th. Stockholders of record on Thursday, August 21st were paid a $0.20 dividend. The ex-dividend date was Thursday, August 21st. This represents a $0.80 annualized dividend and a dividend yield of 0.9%. LeMaitre Vascular's dividend payout ratio (DPR) is presently 38.83%.

Insider Transactions at LeMaitre Vascular

In related news, CEO George W. Lemaitre sold 100,000 shares of the business's stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $93.51, for a total transaction of $9,351,000.00. Following the sale, the chief executive officer owned 1,727,003 shares in the company, valued at $161,492,050.53. The trade was a 5.47% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director John A. Roush sold 6,561 shares of the business's stock in a transaction on Monday, August 11th. The stock was sold at an average price of $92.55, for a total value of $607,220.55. Following the sale, the director owned 2,916 shares in the company, valued at $269,875.80. This represents a 69.23% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 120,815 shares of company stock worth $11,280,206. 9.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On LeMaitre Vascular

Several institutional investors and hedge funds have recently made changes to their positions in the business. Principal Financial Group Inc. raised its stake in shares of LeMaitre Vascular by 3.0% in the first quarter. Principal Financial Group Inc. now owns 111,865 shares of the medical instruments supplier's stock worth $9,385,000 after purchasing an additional 3,248 shares during the last quarter. Compass Planning Associates Inc grew its holdings in shares of LeMaitre Vascular by 91.4% in the first quarter. Compass Planning Associates Inc now owns 11,776 shares of the medical instruments supplier's stock valued at $988,000 after acquiring an additional 5,623 shares in the last quarter. US Bancorp DE grew its holdings in shares of LeMaitre Vascular by 36.0% in the first quarter. US Bancorp DE now owns 1,390 shares of the medical instruments supplier's stock valued at $117,000 after acquiring an additional 368 shares in the last quarter. Johnson Investment Counsel Inc. grew its holdings in shares of LeMaitre Vascular by 34.8% in the first quarter. Johnson Investment Counsel Inc. now owns 29,428 shares of the medical instruments supplier's stock valued at $2,469,000 after acquiring an additional 7,603 shares in the last quarter. Finally, Consolidated Planning Corp bought a new position in shares of LeMaitre Vascular in the first quarter valued at approximately $947,000. Institutional investors own 84.64% of the company's stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.